Barrett's esophagus future or investigational therapies

Jump to navigation Jump to search

Barrett's Esophagus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Barrett's Esophagus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Barrett's esophagus future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Barrett's esophagus future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Barrett's esophagus future or investigational therapies

CDC on Barrett's esophagus future or investigational therapies

Barrett's esophagus future or investigational therapies in the news

Blogs on Barrett's esophagus future or investigational therapies

Directions to Hospitals TreatingBarrett's esophagus

Risk calculators and risk factors for Barrett's esophagus future or investigational therapies

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

  • Biomarkers
  1. Can not be used to confirm the diagnosis of Barrett´s esophagus.
  2. Can not be used to predict risk of progression.
  3. Promissing for the future[1].


  • Endoscopic Therapy
  1. In patients with confirmed high-grade dysplasia with Barrett' esophagus it is more recommended to proceed with endoscopic eradication therapy with radiofrequency ablation (RFA), photodynamic therapy (PDT), or endoscopic mucosal resection (EMR) rather than surveillance.
  2. In patients who have dysplasia in Barrett's esophagus associated with a visible mucosal irregularity it is recommended to proceed with endoscopic mucosal resection (EMR) to determine the T stage of the neoplasia[1].

References

  1. 1.0 1.1 Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. doi:10.1053/j.gastro.2011.01.030. PMID 21376940. Unknown parameter |month= ignored (help)

Template:WH Template:WS